BR112018074472A2 - interfaces proteicas - Google Patents

interfaces proteicas

Info

Publication number
BR112018074472A2
BR112018074472A2 BR112018074472-7A BR112018074472A BR112018074472A2 BR 112018074472 A2 BR112018074472 A2 BR 112018074472A2 BR 112018074472 A BR112018074472 A BR 112018074472A BR 112018074472 A2 BR112018074472 A2 BR 112018074472A2
Authority
BR
Brazil
Prior art keywords
compounds
targeted
dna damage
damage repair
cancer cells
Prior art date
Application number
BR112018074472-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Charly CHAHWAN
Maria SOLOVEYCHIK
Original Assignee
Synthex, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthex, Inc. filed Critical Synthex, Inc.
Publication of BR112018074472A2 publication Critical patent/BR112018074472A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi
    • C12R2001/85—Saccharomyces
    • C12R2001/865—Saccharomyces cerevisiae
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
BR112018074472-7A 2016-05-27 2017-05-26 interfaces proteicas BR112018074472A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662342840P 2016-05-27 2016-05-27
US62/342,840 2016-05-27
US201662384226P 2016-09-07 2016-09-07
US62/384,226 2016-09-07
PCT/US2017/034870 WO2017205852A2 (en) 2016-05-27 2017-05-26 Protein interfaces

Publications (1)

Publication Number Publication Date
BR112018074472A2 true BR112018074472A2 (pt) 2019-03-19

Family

ID=60411842

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018074472-7A BR112018074472A2 (pt) 2016-05-27 2017-05-26 interfaces proteicas

Country Status (9)

Country Link
US (4) US10188691B2 (https=)
EP (2) EP3463414B1 (https=)
JP (3) JP7080878B2 (https=)
CN (2) CN109562138B (https=)
AU (4) AU2017271678B2 (https=)
BR (1) BR112018074472A2 (https=)
CA (1) CA3025423A1 (https=)
MX (2) MX2018014366A (https=)
WO (1) WO2017205852A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017205852A2 (en) 2016-05-27 2017-11-30 Synthex, Inc. Protein interfaces
GB2584211B (en) 2017-11-16 2023-05-24 Synthex Inc Selective modulation of protein-protein interactions
GB2584210B (en) 2017-11-22 2022-03-16 Synthex Inc Peptides for inhibiting RAD51
WO2020223601A1 (en) * 2019-05-01 2020-11-05 Innate Biologics Llc Immunomodulatory compositions and methods
JP7773376B2 (ja) 2019-05-15 2025-11-19 シンセックス， インコーポレイテッド タンパク質の選択的分解
JP2023145812A (ja) * 2020-08-17 2023-10-12 国立大学法人東海国立大学機構 人工タンパク質、Ｒａｓ阻害剤及び抗がん剤

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69636866D1 (en) 1995-04-11 2007-03-15 Gen Hospital Corp Reverse "two-hybrid"-systeme
US5733726A (en) 1995-06-07 1998-03-31 Emory University Cytotoxicity-based genetic selection system (TOXSEL)
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
WO1998007845A1 (en) 1996-08-23 1998-02-26 President And Fellows Of Harvard College Interaction trap assay, reagents and uses thereof
US6037125A (en) 1996-11-05 2000-03-14 Lexicon Genetics Incorporated Disruption of the mammalian RAD51 protein and disruption of proteins that associate with mammalian RAD51 for hindering cell proliferation and/or viability of proliferating cells
US6303302B1 (en) 1997-11-19 2001-10-16 The Whitehead Institute For Biomedical Research Regulation of fungal gene expression
CA2417135C (en) 1997-11-19 2005-04-12 Microbia, Inc. Chimeric pre-activated transcription factors
CA2310624A1 (en) 1997-11-19 1999-05-27 Microbia, Inc. Chimeric pre-activated transcription factors
CA2317816C (en) 1998-01-09 2009-02-17 Tvw Telethon Institute For Child Health Research Peptide detection method
CA2325447C (en) 1998-03-26 2007-08-21 Glaxo Group Limited Assay methods
US6332897B1 (en) 1998-03-27 2001-12-25 Glaxo Wellcome Inc. Assay methods
US6114111A (en) 1998-03-30 2000-09-05 Rigel Pharmaceuticals, Inc. Mammalian protein interaction cloning system
US6316223B1 (en) 1998-03-30 2001-11-13 Rigel Pharmaceuticals, Inc. Mammalian protein interaction cloning system
DE19901008A1 (de) * 1999-01-13 2000-07-20 Deutsches Krebsforsch Peptide zur Inhibierung von HPV E6-Proteinen
AU3733100A (en) 1999-03-09 2000-09-28 Lexicon Genetics Incorporated Compounds that disrupt mammalian rad51 activity
US7270969B2 (en) * 1999-05-05 2007-09-18 Phylogica Limited Methods of constructing and screening diverse expression libraries
AU783233B2 (en) 1999-06-07 2005-10-06 Tet Systems Holding Gmbh & Co. Kg Novel TET repressor-based transcriptional regulatory proteins
US6790607B1 (en) 1999-10-07 2004-09-14 Hybrigen, Inc. Adjustable sensitivity, genetic molecular interaction systems, including protein-protein interaction systems for detection and analysis
CA2386258A1 (en) 1999-10-07 2001-04-12 Hybrigen, Inc. Adjustable sensitivity, genetic molecular interaction systems, including protein-protein interaction systems for detection and analysis
US20020086840A1 (en) 2000-01-26 2002-07-04 Zarling David A. Use of Rad51 inhibitors for p53 gene therapy
AU2001247296A1 (en) 2000-03-06 2001-09-17 Rigel Pharmaceuticals, Inc. In vivo production of cyclic peptides
US7566765B2 (en) 2000-03-06 2009-07-28 Rigel Pharmaceuticals, Inc. Heterocyclic compounds containing a nine-membered carbon-nitrogen ring
US7252952B2 (en) 2000-03-06 2007-08-07 Rigel Pharmaceuticals, Inc. In vivo production of cyclic peptides for inhibiting protein—protein interaction
US7378248B2 (en) 2000-03-06 2008-05-27 Rigel Pharmaceuticals, Inc. In vivo production of cyclic peptides for inhibiting protein-protein interaction
EP1268842B1 (en) 2000-03-08 2006-06-21 Phylogica Limited Improved reverse n-hybrid screening method
US20030211495A1 (en) 2000-03-08 2003-11-13 Richard Hopkins Reverse n-hybrid screening method
AU2001245584B2 (en) 2000-03-08 2007-02-08 Phylogica Limited Improved reverse n-hybrid screening method
GB0006572D0 (en) 2000-03-17 2000-05-10 Isis Innovation Novel transcription transactivator protein
WO2003013488A2 (en) 2001-08-09 2003-02-20 Pangene Corporation Methods and compositions for inhibiting rad51
US20030229004A1 (en) 2002-03-20 2003-12-11 Pangene Corporation Modulation of tumor cells using BER inhibitors in combination with a sensitizing agent and DSBR inhibitors
WO2004042064A2 (en) * 2002-11-07 2004-05-21 Imperial College Innovations Limited Disorders of lipid metabolism
JP2004215624A (ja) * 2003-01-17 2004-08-05 Celestar Lexico-Sciences Inc 相互作用インヒビターの検出方法、相互作用インヒビターライブラリーおよびインヒビター検出キット
ITMI20030821A1 (it) * 2003-04-18 2004-10-19 Internat Ct For Genetic En Gineering And Polipeptidi chimerici e loro uso.
US20060003391A1 (en) * 2003-08-11 2006-01-05 Ring Brian Z Reagents and methods for use in cancer diagnosis, classification and therapy
JP2005095613A (ja) 2003-09-04 2005-04-14 Taiyo Parts Kk 昇降装置
CN1905864B (zh) * 2003-12-01 2011-04-06 库多斯药物有限公司 用于治疗癌症的dna损伤修复抑制剂
WO2005095613A1 (ja) 2004-03-30 2005-10-13 Genomidea Inc. Rad51の発現抑制剤、該発現抑制剤を有効成分として含む医薬、及びその使用
WO2006052391A2 (en) 2004-10-14 2006-05-18 Rigel Pharmaceuticals, Inc. Heterocyclic inhibitors of ires-mediated translation and methods of use thereof
RU2446796C2 (ru) 2006-12-26 2012-04-10 Фармасайкликс, Инк. Способ использования ингибиторов гистондеацетилазы и мониторинга биомаркеров в комбинированной терапии
US7892823B2 (en) 2007-02-06 2011-02-22 Geneprotech, Inc. Methods and systems for high homologous recombination (“HR”) targeting efficiency
US8759089B2 (en) 2007-02-06 2014-06-24 Geneprotech, Inc. Methods and systems for high homologous recombination (“HR”) targeting efficiency
US8105493B2 (en) 2007-06-29 2012-01-31 Jnc Corporation Aggregation and dispersion methods of magnetic particles, separation and detection methods using the same and detection kit
WO2009018219A2 (en) 2007-07-28 2009-02-05 University Of Chicago Methods and compositions for modulating rad51 and homologous recombination
US9518097B2 (en) 2007-11-09 2016-12-13 Board Of Trustees Of Michigan State University Identification and use of genes encoding amatoxin and phallotoxin
US9273100B2 (en) 2007-11-09 2016-03-01 Board Of Trustees Of Michigan State University Use of Galerina marginata genes and proteins for peptide production
WO2012019157A2 (en) 2010-08-06 2012-02-09 The Regents Of The University Of California Expression and purification of fusion protein with multiple mbp tags
US9249410B2 (en) 2010-12-15 2016-02-02 The Johns Hopkins University Two-hybrid based screen to identify disruptive residues at multiple protein interfaces
AU2012275841A1 (en) * 2011-06-27 2014-01-16 The Jackson Laboratory Methods and compositions for treatment of cancer and autoimmune disease
US10912761B2 (en) 2012-11-30 2021-02-09 The University Of Chicago Methods and compositions involving RAD51 inhibitors
US20170014360A1 (en) 2014-03-10 2017-01-19 The University Of Chicago Methods of treating cancer using rad51 small molecule stimulators
WO2016140971A1 (en) 2015-03-02 2016-09-09 The Regents Of The University Of California Novel rad51 inhibitors and uses thereof
WO2017205852A2 (en) 2016-05-27 2017-11-30 Synthex, Inc. Protein interfaces
GB2584211B (en) 2017-11-16 2023-05-24 Synthex Inc Selective modulation of protein-protein interactions

Also Published As

Publication number Publication date
EP3463414C0 (en) 2023-09-13
JP2019527066A (ja) 2019-09-26
EP3463414A2 (en) 2019-04-10
EP4269427A3 (en) 2023-11-22
CN109562138B (zh) 2023-03-21
AU2022259709A1 (en) 2022-11-24
MX2023002591A (es) 2024-02-08
CN116217657A (zh) 2023-06-06
WO2017205852A3 (en) 2018-01-25
WO2017205852A2 (en) 2017-11-30
US20250177474A1 (en) 2025-06-05
US20170368132A1 (en) 2017-12-28
AU2017271678A1 (en) 2018-12-13
AU2024204362A1 (en) 2024-07-11
AU2021205010A1 (en) 2021-08-05
CA3025423A1 (en) 2017-11-30
US10188691B2 (en) 2019-01-29
CN109562138A (zh) 2019-04-02
JP7479421B2 (ja) 2024-05-08
JP7080878B2 (ja) 2022-06-06
AU2017271678B2 (en) 2021-05-06
MX2018014366A (es) 2019-04-11
AU2021205010B2 (en) 2022-08-11
EP4269427A2 (en) 2023-11-01
US20210252100A1 (en) 2021-08-19
US20190216879A1 (en) 2019-07-18
EP3463414B1 (en) 2023-09-13
JP2022119883A (ja) 2022-08-17
JP2024099695A (ja) 2024-07-25
US12214008B2 (en) 2025-02-04
EP3463414A4 (en) 2019-10-23

Similar Documents

Publication Publication Date Title
BR112018074472A2 (pt) interfaces proteicas
CY1125476T1 (el) Καινοφανης αμφιειδικη μορφη καταλληλη για χρηση σε διερευνητικο ελεγχο υψηλης αποδοσης
BR112019000327A8 (pt) Anticorpo para anticlaudina 18a2 e uso do mesmo
BR112018002274A2 (pt) anticorpos anti-pd-1
BR112018000768A2 (pt) anticorpos anti-pd-1, anticorpos anti-pd-1 ativáveis e métodos de uso dos mesmos
BR112016014293A2 (pt) região de fragmento cristalizável canino, anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição farmacêutica, e, método para aumentar a atividade de uma célula imune
BR112019012354A2 (pt) anticorpos apenas de cadeia pesada anti-bcma
BR112015022852A2 (pt) mecanismos de processamento de vetor que tem configurações de percurso de dados programáveis para proporcionar processamento de vetor de múltiplos modos, e processadores de vetor, sistemas, e métodos, relacionados
MX2017003565A (es) Anticuerpos anti-edad para el tratamiento de inflamacion y trastornos autoinmunes.
EA202090931A2 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
BR112016004020A2 (pt) introgressão de alelo não meiótico eficiente
BR112014031891A2 (pt) direcionamento genético nas plantas utilizando vírus de dna
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
BR112015031639A2 (pt) integração alvo
BR112018013653A2 (pt) anticorpos anti-pd-1
BR112017013956B8 (pt) Proteínas de fusão de citocinas
CY1123144T1 (el) Επαγωγη καρδιακης αναγεννησης μe microrna
BR112018008390A2 (pt) composições e métodos para transdução tumoral
BR112016026136A2 (pt) composições e métodos para aumentar o desenvolvimento e o rendimento vegetal
BR112016004324A2 (pt) anticorpos
BR112017023131A2 (pt) anticorpos anti- fcrn
BR112016008477A2 (pt) Corpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica e usos do anticorpo
BR112017013576A2 (pt) produção melhorada de lipídios de núcleo em leveduras oleaginosas
BR112019010034A2 (pt) fator viii alvejado de hemácia e método de uso do mesmo

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/05/2017, OBSERVADAS AS CONDICOES LEGAIS